Human papillomavirus, human immunodeficiency virus and immunosuppression

Area of Science:

• Immunology
• Oncology
• Infectious Diseases

Background:

• Human immunodeficiency virus (HIV) and human papillomavirus (HPV) co-infection is common, particularly in women.
• HIV alters cell-mediated immunity, increasing susceptibility to HPV and potentially reactivating latent infections.
• HIV-positive women face a significantly higher risk of cervical cancer (2- to 22-fold increase).

Purpose of the Study:

• To review the interaction between HIV and HPV infections.
• To examine the impact of co-infection on cervical and anal cancer risks.
• To discuss the current status and future directions of HPV vaccination and prevention strategies in HIV-positive individuals.

Main Methods:

• Review of linkage studies between HIV/AIDS and cancer registries.
• Analysis of data on HPV type prevalence in invasive cervical carcinoma (ICC).
• Discussion of ongoing research on HPV vaccine safety, immunogenicity, and efficacy in HIV-positive populations.

Main Results:

• HPV types 16/18, responsible for most cervical cancers, show similar prevalence in HIV-negative and HIV-positive women.
• HIV-positive individuals, especially men who have sex with men, have a greatly increased incidence of anal cancer.
• Adolescents with perinatally acquired HIV have higher HPV infection rates and lower seroconversion titers to HPV vaccine compared to HIV-negative individuals.

Conclusions:

• The biological interaction between HIV and HPV requires further investigation.
• Screening for anal cancer precursors is effective, but its impact on cancer reduction needs demonstration.
• Further studies are needed on HPV vaccine efficacy and prevention strategies like male circumcision in HIV-positive individuals.